Malignant Hematology

Question 1

Immunophenotype for HCL variant

Answer 1

BRAF V600E negative

CD19, CD20, CD22 positive

Question 2

Who to use high dose dauno in

Answer 2

age <65

Question 3

Treatment of APL after CR2

Answer 3

Auto if PCR neg

Allo if PCR pos

Question 4

Steroid resposiveness in COP vs BO

Answer 4

COP - responsive

BO - not responsive

Question 5

17p in CLL prognosis

Answer 5

Very bad prognosis

Question 6

11q in CLL prognosis

Answer 6

Bad prognosis

Question 7

13q in CLL prognosis

Answer 7

Very good prognosis

Question 8

Treatment of 17p CLL

Answer 8

ibrutinib

Question 9

Immunophenotype of HCL (4)

Answer 9

CD19+, CD20+, CD103+, CD11c+

Question 10

Ibrutinib resistance mutation

Answer 10

C481S

Question 11

Difference between classical and variant HCL mutation

Answer 11

BRAF V600E

Question 12

Third line treatment for HCL

Answer 12

Moxetumomab pasudotox-tdfk

Question 13

Treatment of PRCA in CLL

Answer 13

Immunosuppresive

Question 14

Treatment of Stage I-II unfavorable HL

Answer 14

ABVD x 4 followed by ISRT

Question 15

Unfavorable features for HL (5)

Answer 15

Bulky mediastinum
>10cm disease
B symptoms
ESR >50
>3 sites of disease

Question 16

IHC finding for nodular lymphocyte predominant HL

Answer 16

CD20

Question 17

Treatment of stage III-IV HL if Deauville 1-3 after 2 cycles of ABVD

Answer 17

AVD x 4 more cycles

Question 18

Treatment of stage III-IV HL if Deauville 4+ after 2 cycles of ABVD

Answer 18

BEACOPP

Question 19

Treatment of HL during pregnancy

Answer 19

ABVD in the second trimester

Question 20

MOA of siltuximab

Answer 20

IL-6 antagonist

Question 21

t(3;14) for DLBCL prognosis

Answer 21

Good prognosis

Question 22

Treatment of Stage IA nodular lymphocyte predominant HL

Answer 22

ISRT alone

Question 23

Karyotype for alkalating agent MDS/AML

Answer 23

-5 or -7

Question 24

Childhood MDS with -7 gene mutation

Answer 24

SAMD9

Question 25

Dosing of lenalidomide in HD

Answer 25

5mg daily, after dialysis

Question 26

Adverse risk MM cytogenetics (5)

Answer 26

``` t(4;14) t(14;20) t(14;16) del17p amp 1q21 ```

Question 27

Indications for plasmapheresis in WM (2)

Answer 27

Hyperviscosity symptoms OR | IgM >4000

Question 28

Karyotype in FL

Answer 28

t(14;18)

Question 29

Definition of grade 3b FL

Answer 29

15 centroblasts or sheets of centroblasts

Question 30

MALT t(11;18) meaning for response to triple therapy

Answer 30

Lack of benefit

Question 31

Lymphoma associated with HCV

Answer 31

Splenic marginal zone lymphoma

Question 32

Treatment of aggressive Mantle Cell in young patient

Answer 32

HyperCVAD

Question 33

Treatment of NK/T-cell lymphoma

Answer 33

Chemoradiation

Question 34

Rosai Dorfman disease clinical symptoms

Answer 34

Hisitiocytes | LAD

Question 35

T-cell prolymphocytic leukemia karyotype

Answer 35

inv(14)(q11q32)

Question 36

Plasmablastic lymphoma treatment

Answer 36

EPOCH with IT chemo

Question 37

Treatment of refractory mantle cell lymphoma

Answer 37

BTK inhibitors R/R VEN

Question 38

Definition of bulky disease in DLBCL

Answer 38

>7.5cm

Question 39

Burkitt lymphoma translocation

Answer 39

t(8;14)

Question 40

Mantel cell lymphoma translocation

Answer 40

t(11;14)

Question 41

Follicular lymphoma translocation

Answer 41

t(14;18)

Question 42

Infections with PI3K inhibitors (2)

Answer 42

CMV | PJP

Question 43

Mutation associated with Erdheim-Chester disease

Answer 43

BRAF V600E

Question 44

Diagnostic antigens in mantle cell lymphoma

Answer 44

CCND1 | SOX11

Question 45

EBV+ lymphoma with rash an effusions

Answer 45

Angioimmunoblastic T-cell lymphoma

Question 46

Brexucabtagene autoleucel disease

Answer 46

Mantle cell lymphoma

Question 47

Maintenance after auto for mantle cell

Answer 47

Rituximab x 3 years

Question 48

Adverse cytogenetics in AL amyloid

Answer 48

t(11;14)

Question 49

Treatment of ATTR amyloidosis

Answer 49

liver transplantation

Question 50

Treatment of ATTR amyloidosis with peripheral neuropathy

Answer 50

Patisiran

Question 51

Treatment of ATTR amyloidosis with cardiac involvement in non liver transplant setting

Answer 51

Tafamidis

Question 52

HMR in MF

Answer 52

EZH2, ASXL1, SRSF2, IDH1/2

Question 53

BCL6 positive malignancy

Answer 53

Follicular lymphoma

Question 54

Most permissive loci for allo transplant

Answer 54

HLA-DQ

Question 55

Most common fungal infection with ibrutinib

Answer 55

Aspergillosis

Question 56

Risk for post transplant LPD

Answer 56

GVHD

Question 57

TKI to avoid in DM

Answer 57

Nilotinib

Question 58

Upfront treatment of ALCL

Answer 58

Brentuximab+CHP

Question 59

Treatment of elderly CLL

Answer 59

Obinutuzumab + Chlorambucil

Question 60

Treatment of 17p CLL R/R to BTK

Answer 60

Venetoclax

Question 61

Time after alloSCT for live vaccines

Answer 61

2 year

Question 62

Timing of PTLD post transplant as it relates to EBV related

Answer 62

<1 year: EBV related | >1 year: not EBV related

Question 63

Stains for erythroleukemia (2)

Answer 63

glycophorin A | CD36